Title:
USES OF DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES
Document Type and Number:
WIPO Patent Application WO/2023/054423
Kind Code:
A1
Abstract:
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
Inventors:
NAOI SOTARO (JP)
FENG SHU (SG)
IGAWA TOMOYUKI (JP)
HO SHU WEN SAMANTHA (SG)
MATSUDA YUTAKA (JP)
MIKAMI HIROFUMI (JP)
KAWAI YUMIKO (JP)
TSUNENARI TOSHIAKI (JP)
FENG SHU (SG)
IGAWA TOMOYUKI (JP)
HO SHU WEN SAMANTHA (SG)
MATSUDA YUTAKA (JP)
MIKAMI HIROFUMI (JP)
KAWAI YUMIKO (JP)
TSUNENARI TOSHIAKI (JP)
Application Number:
PCT/JP2022/036063
Publication Date:
April 06, 2023
Filing Date:
September 28, 2022
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K39/395; A61K31/4745; A61K31/704; A61K31/7048; A61K33/245; A61K45/00; A61P35/00; A61P43/00
Domestic Patent References:
| WO2020067399A1 | 2020-04-02 | |||
| WO2019131988A1 | 2019-07-04 | |||
| WO2020067419A1 | 2020-04-02 |
Foreign References:
| US20210301016A1 | 2021-09-30 |
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF:
Previous Patent: POLYESTER RESIN
Next Patent: WELD STRUCTURE, ELECTRONIC COMPONENT MODULE, AND WELDING METHOD
Next Patent: WELD STRUCTURE, ELECTRONIC COMPONENT MODULE, AND WELDING METHOD